Background: In order to predict the occurrence of worsening renal function (WRF) and of WRF plus in-hospital death, 101 emergency department (ED) patients with acute decompensated heart failure (ADHF) were evaluated with testing for amino-terminal pro-B-type natriuretic peptide (NT-proBNP), BNP, sST2, and neutrophil gelatinase associated lipocalin (NGAL).
Introduction
When evaluating patients with acutely decompensated heart failure (ADHF) in the emergency department (ED), prompt diagnosis and risk stratification with consequent appropriate treatment is the key to superior outcome [1, 2] . Part of the intricacy of caring for patients with ADHF is to manage the comorbidities that may simultaneously occur [2] . Kidney dysfunction in ADHF patients is quite common, manifesting as acute kidney injury (AKI) in a significant percentage; this results in worsening renal function (WRF) [3] [4] [5] [6] . WRF occurs in up to 25% of patients with ADHF, and is associated with a considerably higher risk for adverse outcome [7] . In this regard, HF and kidney dysfunction are so important that the term 'cardiorenal syndrome' has been coined to describe their deleterious intersection [8] [9] [10] .
Mechanistically, the cause of WRF in the setting of ADHF is complex, but includes contributions from venous congestion, impairments in cardiac output, concomitant medical/renal disease, as well as adverse effects of medications used in HF [1, 10] . Unfortunately, the clinical ability to predict WRF remains limited. Given the poor outcomes of patients suffering from WRF in the context of ADHF, an objective method to predict the onset of WRF is desirable, and might logically be useful for therapeutic decision making in these patients. Estimated glomerular filtration rate (eGFR) is considered the current standard method to make diagnosis of WRF [9] . Unfortunately, eGFR often changes slowly in response to ACI, making it unsuitable for its timely diagnosis [9] . Accordingly, newer methods to recognize AKI that leads to WRF would be desirable. In this regard, newer biomarkers of kidney damage [including neutrophil gelatinase-associated lipocalin (NGAL)] may provide the ability to detect kidney injury earlier and more specifically [11, 12] ; recent data suggest blood NGAL measurements may be useful in the early diagnosis of AKI and WRF [12, 13] , but data are mixed in this regard. Other biomarkers that may have a role in predicting WRF include those related to fluid retention and myocardial stretch. The B-type natriuretic peptides [BNP and aminoterminal pro-BNP (NT-proBNP)] are recognized biomarkers of cardiac function, and both predict outcome in ADHF patients [14] . Similarly, soluble (s)ST2 is an interleukin-1 receptor family member up-regulated as consequence of cardiomyocyte strain with proven prognostic merit in patients suffering from acute myocardial infarction and HF [15] [16] [17] . So far no results are present in the literature comparing the utility of NGAL, natriuretic peptides and sST2 in the prediction of WRF in patients with ADHF. The aim of our study was to compare the role of these biomarkers for the diagnosis and prognosis of cardiorenal syndrome in patients with ADHF in the ED setting.
Materials and methods
The Biomonitoring and Cardiorenal Syndrome in Heart Failure (BIONICS-HF) Trial (Clinicaltrials.gov NCT#01570153) prospectively enrolled subjects between April and July 2012 at two tertiary care academic medical center members of the Global Research on Acute Conditions Team: the Massachusetts General Hospital ( Boston, MA, USA), and Sant'Andrea Hospital (Rome, Italy). All study procedures were approved by local institutional review boards. The study planned to examine the ability of two strategies for predicting CRS in patients with ADHF: bioimpedance vector analysis [18] , a non-invasive method for assessing total body hydration, as well as circulating biomarkers. For the purpose of this report, we focus on biomarker results.
In an effort to validate results from the prospectively enrolled subjects, we calculated rates of WRF as a function of NT-proBNP, BNP, and NGAL among 162 consecutively enrolled subjects previously presenting with ADHF at Lariboisiere Hospital in Paris, France (Clinical Trials.gov NCT#01374880).
Patient enrollment
In a prior analysis, we found 36.8% of subjects with ADHF developed WRF [19] , defined as a rise of serum creatinine by 0.3 mg/dL (or rise ≥ 25%) from baseline [3] [4] [5] [6] . Based on this prevalence, an estimate of 100 subjects with ADHF was determined to provide sufficient power for the primary outcome. Given this prevalence, assuming 80% power to detect 20% superiority in accuracy of the multimarker approach for predicting WRF compared to a model of clinical variables alone, a total of 100 subjects with ADHF would provide sufficient power. We have chosen the logistic regression analysis because we were not able to accurately define the point of developing WRF (sCR were not performed each day); further, for time horizons as short as that used in the present analysis logistic regression is accepted for modeling.
Sequential patients were screened during working hours. Inclusion criteria included moderate or severely symptomatic ADHF (including de novo cases) requiring addition or intensification of diuretic therapy. Exclusion criteria included renal failure requiring current renal replacement therapy, ≥ 8 h from first dose of intravenous diuretic, and unwillingness or inability to participate in study procedures. The protocol was designed following the criteria of the declaration of Helsinki and was approved by the ethical committee at each participating hospital. Of note, the dose and method of administration of intravenous loop diuresis (e.g., bolus vs. continuous infusion) was at the discretion of the managing physician at each site. No patients received saline loading prior to diuretic administration.
Data collection
Baseline demographics, vital signs, and results of physical examination were recorded after informed consent was signed. Clinical characteristics collected included past medical history including that for chronic kidney disease (defined as previously established eGFR < 60 mL/min/1.73 m 2 ). Other medical background was abstracted on the basis of prior medical records, patient treatment, and/or self-reports. The informed consent was signed just after considered the eligibility of patients for the study at the moment of admission in ED (mean time from presentation to the data and blood sample collection was 15.3 ± 2.3 min). Blood was drawn soon after the informed consent and processed as noted below.
Blood analysis
Blood was drawn into tubes containing ethylenediaminetetraacetic acid (EDTA) or no anticoagulant, and spun for 15 min at 4000 g. Samples were immediately aliquoted to freezer tubes and frozen at -80 °C for biomarker measurement following the completion of the trial.
All biomarkers from the derivation and validation cohort were run in the same laboratory, using the same methodology and blinded to clinical variables. Biomarkers of cardiomyocyte stretch included NT-proBNP (Roche Diagnostics, Indianapolis, IN, USA), BNP (Alere Triage BNP, San Diego, CA, USA), and sST2 (Presage ST2, Critical Diagnostics, San Diego, CA, USA). Biomarkers of renal function included: blood urea nitrogen (BUN), serum creatinine (sCr; Roche Diagnostics), and estimated glomerular filtration rate (eGFR; estimated using the simplified modification of diet in renal disease equation [9] . As a biomarker of renal injury, we also measured NGAL (Alere, San Diego, CA, USA). Clinicians were blind to sST2 and NGAL results.
The intra-and inter-assay coefficients of variation for each method are shown in Supplemental text.
Outcomes
The primary endpoint of the study was the ability of objective measures to predict WRF defined as a rise of serum creatinine by 0.3 mg/ dL (or rise ≥ 25%) from baseline [3] [4] [5] [6] during the current admission. In patients meeting the criteria of WRF, the etiology of renal dysfunction was judged by two study physicians at each site blinded to the results of biomarkers, using standard criteria [3] [4] [5] [6] . In addition, among those patients with WRF, characterization using RIFLE classification was performed [8] .
Statistical analysis
Baseline variables of study participants as a function of WRF were calculated. Continuous variables were summarized as mean ± standard deviation if normally distributed, while non-normally distributed continuous variables were summarized as median and inter-quartile range; Kolmogorov-Smirnov testing identified states of non-normality. Variables were compared using the Student's t-test or χ 2 -test as appropriate, while the Mann-Whitney U-test was used for continuous variables in the states of non-normality. Results from biomarker testing were examined as a function of RIFLE classification using the Kruskal-Wallis test. Receiver operating characteristic (ROC) tests compared the results of each biomarker for predicting WRF, expressed as area under the ROC. From ROC testing, an optimal threshold for predicting WRF was identified using the method of Youden. Univariable comparisons between all baseline characteristics (including history of chronic kidney disease, clinical signs of congestion, BUN, creatinine, eGFR, and more novel biomarker results) were used to identify candidate variables for entry to a multivariable logistic regression model; in both uni-and multivariable models, we used WRF as the dependent variable; only those with a p-value < 0.05 were retained for multivariable modeling. Biomarkers were examined both as log-transformed continuous variables as well as dichotomously. Odds ratios (OR) and 95% confidence intervals (CI) were generated. In order to better examine the prognostic importance of biomarker combinations, subjects were grouped relative to optimal cut-offs for natriuretic peptides plus NGAL, and again examined in uni-and multivariable logistic regression. Rates of WRF as a function of results of candidate predictors were examined. To compare results from the derivation to validation cohorts, we used likelihood ratio testing to assess whether any statistical differences in the validity of the models existed in each biomarker grouping. ROC analyses were performed using Analyse It software (Leeds, UK), while all other statistical analyses were performed using either PASW Statistics Version 17.0 (Chicago, IL, USA) or SAS (Version 9.2; Cary, NC, USA). All p-values are two-sided with a value of < 0.05 considered significant.
Results
In total 101 consecutive ED patients with ADHF (mean age 74.6 ± 11.5 years) were enrolled and included, 26 subjects (25.7%) developed WRF, and eight (7.9%) died during hospitalization; of the eight dying, all but two also had WRF.
Baseline characteristics
Baseline characteristics as a function of WRF are detailed in Table 1 , which demonstrates that the demographics, clinical presentation, and diagnostic studies of subjects who subsequently developed WRF were generally comparable to those who did not. The results of clinical examination were similar between those who developed WRF following presentation, with the notable exception of a higher frequency of pleural effusion on chest radiography among those who later developed WRF. Intriguingly, baseline measures of renal function were not significantly different between those who did or did not develop WRF.
Biomarkers and outcomes
At baseline, concentrations of NT-proBNP, BNP, and NGAL were significantly higher in those who developed WRF following presentation than in those who did not (Table 2) . In contrast, baseline sST2 concentrations were not significantly different between the two groups.
All but one subject with WRF was judged to have Type 1 cardiorenal syndrome [20, 21] ; by further categorization using RIFLE criteria, the majority of those developing WRF were characterized as Risk (n = 22), while two were Injury, and two were Failure. Considered in this regard, median concentrations of NT-proBNP, BNP, and NGAL were each higher in a stepwise fashion across these groups, but with few subjects in the more severe categories. When examined in ROC analyses using WRF as the gold standard outcome, BNP, NT-proBNP, and NGAL had modestly significant AUC, while sST2 did not (Figure 1 ). Using ROC analyses, the optimal cut-offs for WRF were then identified. With respect to WRF, the optimal NTproBNP, BNP, and NGAL cut-offs were 2890 pg/mL, 553 pg/mL, and 196 pg/mL, respectively (Table 3) ; each had modest accuracy. Use of median concentrations for NTproBNP, BNP, and NGAL rather than ROC-optimal cutoffs produced generally similar operating characteristics (results not shown).
We then performed univariable logistic regression analyses for all variables, using WRF as the dependent variable (Table 4) . In this analysis, dichotomously modeled (but not continuous) NT-proBNP, BNP, and NGAL were predictive of WRF. Compared to the results from single biomarkers, however, the combination of elevated NT-proBNP plus elevated NGAL or elevated BNP plus elevated NGAL was a considerably stronger predictor of both outcome measures. This finding remained in multivariable analyses (Table 4) .
Given the additive value of NT-proBNP/BNP and NGAL, we then categorized patients as a function of their biomarkers -both biomarkers below optimal cutoffs, one biomarker elevated, both biomarkers elevated -and found the lowest frequency of future WRF was seen in those with both biomarkers below optimal cutoffs, and the highest frequency in those with elevation of both markers (Figure 2 ). Compared to a referent group with both markers below optimal cut-offs, when both Table 3 Operating characteristics of various biomarkers at the ROC optimal cut-offs for the WRF. Candidates for this application had modest accuracy. 
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Validation
In an effort to validate our results, we calculated rates of WRF as a function of NT-proBNP, BNP, and NGAL among 162 consecutively enrolled subjects with ADHF (Table 1) from Lariboisiere Hospital in Paris, France (Clinical Trials. gov NCT#01374880). This group differed in many ways from ours; the derivation group was more likely to have histories of CKD, worse LVEF and more history of coronary artery disease, among other differences. Despite these differences, generally similar performance of biomarkers was seen to predict WRF (Supplemental Table 1 Using the same biomarker thresholds used in the derivation cohort, as shown in Figure 3 , similar results to ours were found, such that with elevation in both natriuretic peptides and NGAL, the highest rates of CRS were seen; in likelihood ratio testing, results of predictive models in these highest risk groups were not statistically significantly different (p = 0.56).
Discussion
In this prospective analysis of 101 subjects with ADHF presenting to two tertiary care medical centers in Italy and the US, we found that WRF was common, affecting more than 25% of our patients. Notably, baseline clinical variables were largely similar between those who did or did not develop WRF, as was the intensity and method of initial diuretic therapy.
Part of the challenge in managing WRF is lack of tools to recognize its imminent presence. This is partially due to the fact that serum creatinine or eGFR are poor markers for early detection of renal dysfunction because as long as 48 h may pass from kidney injury before renal function worsens [12] . Moreover, serum creatinine measurement is greatly influenced by several renal and non-renal factors, including changes in muscular mass, malnutrition, race, age, gender and also certain medications [22] [23] [24] . This renders serum creatinine (or eGFR) less useful for the early diagnosis of WRF, resulting in obvious risk for delay in appropriate treatment. Additionally, as WRF may be caused by a number of factors besides AKI, predicting its onset is challenging. The identification of a means to predict WRF prior to onset of rise in creatinine would be of great help. Other renal biomarkers such as BUN may be of prognostic importance for mortality, but have not consistently predicted onset of WRF (as in our study). Based on the importance of congestion as a mechanism of risk for WRF, we previously suggested the combination of a natriuretic peptide plus a marker of renal injury such as NGAL may be of greater value to predict WRF [18] ; our present results support this suggestion. In our study the combination of NT-proBNP ≥ 2840 pg/mL and NGAL ≥ 196 ng/mL or BNP ≥ 553 pg/mL and NGAL ≥ 196 ng/mL predicted WRF with OR 4.20 (95% CI 1.2-15.0; p = 0.03) or OR 4.20 (95% CI 1.3-13.1; p = 0.01), respectively. These results suggest the combination of stigmata of volume overload plus renal injury can sharpen the diagnostic accuracy for WRF on the basis of Type 1 CRS. Lending further support is the observation that the presence of pleural effusion on chest radiography (indicative of more severe and chronic congestion) was an independent predictor of WRF itself.
Importantly, we validated our results in a separate cohort; the use of a validation cohort adds considerable strength to our study. Despite substantial differences in baseline characteristics and treatment, our results were consistent in this validation cohort. This suggests that regardless of baseline risk and early management strategies, objective testing with biomarkers may be of some use to predict risk for WRF. While an elevated natriuretic peptide value has been previously linked to progression of chronic kidney disease over time [24, 25] , the link between elevation in NTproBNP or BNP and risk for acute WRF is more novel, and suggests a biomarker strategy may be useful to objectively define the state of 'cardiorenal syndrome' [26] .
NGAL has received attention recently as a biomarker of kidney injury in both acute [13, 27] and chronic settings [28] ; it is a 25 kilodalton bacteriostatic siderophore that is expressed in a wide range of tissues. NGAL has a role in the growth, differentiation and protection of several cell types, including renal epithelia. In those with AKI, concentrations of NGAL rise in blood and urine several days prior to manifest changes in conventional measures of renal function. Our results are comparable to those of Aghel [13] and MacDonald [27] , where median NGAL concentrations and their predictive value for WRF were similar. In contrast, Breidthardt et al. did not find NGAL to be predictive of WRF in adjusted analyses [29] . Moreover, our results extend the results of prior studies by adding the joint measurement of natriuretic peptides, which considerably strengthens the diagnostic and predictive values of NGAL for WRF [13, 27] . Presumably the use of NT-proBNP or BNP allows for more accurate characterization of the cause of NGAL elevation. Despite data linking sST2 with ADHF presence as well as elevation in central venous pressures (the latter being an important cause of cardiorenal syndrome) [15] [16] [17] , we did not find sST2 to be useful for predicting WRF.
Limitations
A major limitation of our study is its small size, which limits the power of statistical calculations. This presumably led to an inability to identify statistically significant links between log-transformed biomarker values and outcome, while dichotomous modeling did. As well, with our small size, we could not divide patients into even more refined risk groups other than 'high risk' and 'low risk' or examine the ramification of individual marker elevations; given the multimarker approach examined, this would have led to substantial decrease in accuracy due to the large number of groups created. Despite these limitations, our study was prospective and designed with a priori powering assumptions regarding the incidence of the primary endpoint, which were met with a significant result. The addition of a validation cohort helps to address this concern, and suggests portability of our results. Nonetheless, the small size of the analysis makes our finding hypothesis generating only. Another issue is that clinicians were not blinded to natriuretic peptide results, which may have affected behavior around HF care. Cystatin C containing formulas for eGFR estimation may be more accurate than the MDRD equation, however, we lack cystatin C results in this cohort, which is a limitation. Lastly, we used logistic regression analysis for assessing predictive value for WRF given the extremely low likelihood for proportional hazards to be different over such a short period of time, and also due to different time points for sCr measurement.
In conclusion, our findings support the previous hypothesis that a multimarker approach with BNP or NTproBNP plus NGAL at the moment of admission might provide a more objective way to define 'cardiorenal' syndrome [26] . Compared to the definition currently in use, which relies on the recognition of rise in serum creatinine several days after the initial insult to the kidneys has occurred, our strategy provides considerable lead time with the knowledge of impending renal dysfunction. It is tempting to speculate that the ability to identify a patient at risk for WRF earlier might be leveraged to better select specific therapies in order to reduce future risk. However, as our study is underpowered to make it definitive, we believe a large, pivotal study focused on the role of biomarker testing for prediction of cardiorenal syndrome is now warranted.
